Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
CING
$3.87+Infinity%1D
Analyst Views on CING
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.150
Low
8.00
Averages
12.00
High
16.00
Current: 4.150
Low
8.00
Averages
12.00
High
16.00
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$17 -> $16
2025-11-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$17 -> $16
2025-11-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.
Roth Capital
NULL
to
Buy
upgrade
$10 -> $17
2025-10-14
Reason
Roth Capital
Price Target
$10 -> $17
2025-10-14
upgrade
NULL
to
Buy
Reason
Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$11 -> $10
2025-08-20
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$11 -> $10
2025-08-20
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $10 from $11 but keeps a Buy rating on the shares. The firm's post-Q2 call with the company's management has further strengthened its conviction for CTx-1301 regulatory acceptance in October and potential approval by mid-2026, the analyst tells investors in a research note. Assuming the NDA receives acceptance with an assigned PDUFA date, Roth expects a slew of launch preparation activities focused on disseminating CTx-1301's value in the crowded ADHD market, the firm added.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$12 -> $11
2025-05-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $11
2025-05-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027.
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
